Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston
Tumor-localizing properties of bispecific antibody demonstrated by live imaging Lund, Sweden, April 10, 2019 – Alligator Bioscience (Nasdaq ...
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Lund, Sweden, April 2, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ...
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Lund, Sweden, March 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for th ...
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody Lund, Sweden, March 7, 2019 – Alligator Bioscience (Nasdaq St ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience starts clinical phase I study with ATOR-1015
A first-in-class bispecific CTLA-4 antibody Lund, Sweden, December 11, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announ ...
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cance ...
Alligator Bioscience to receive million-dollar payments – AbClon partner exercises option
Lund, Sweden, November 7, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than U ...
Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144 Lund, Sweden, October 30, 2018 – Alligator Bi ...